Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines

The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022. 313 of S. pneumonia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista española de quimioterapia 2023-12, Vol.36 (6), p.597-603
Hauptverfasser: Zaragoza Vargas, G, Cacho Calvo, J, Martínez-Arce, R, Molina Arana, D, Ramos Blázquez, B, Pérez Abeledo, M, Sanz Moreno, J C
Format: Artikel
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 603
container_issue 6
container_start_page 597
container_title Revista española de quimioterapia
container_volume 36
creator Zaragoza Vargas, G
Cacho Calvo, J
Martínez-Arce, R
Molina Arana, D
Ramos Blázquez, B
Pérez Abeledo, M
Sanz Moreno, J C
description The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022. 313 of S. pneumoniae strains were studied. Serotyping was carried out by latex agglutination (Pneumotest-latex) and the Quellung reaction. In addition, the minimal inhibitory concentration (MIC) was determined against penicillin, erythromycin and levofloxacin by the concentration gradient method (E-test) according the EUCAST breakpoints. The most frequent serotypes throughout the study period were 8, 3, 19A, 1, 11A and 22F corresponding to 46.6% of the isolates. Along 2008-2012 the serotypes 3, 1, 19A, 7F, 6C and 11A represented altogether 53.6% of the isolates. Between 2013 and 2017 the serotypes 3, 8, 12F, 19A, 22F and 19F grouped 51% of the isolates. During 2018-2022 the serotypes 8, 3, 11A, 15A, 4 and 6C included the 55.5% of the cases. In total 5 strains (1.6%) were penicillin resistant, 64 (20.4%) erythromycin resistant and 11 (3.5%) levofloxacin resistant. The MIC50 and MIC90 levels maintained stables along the time. The conjugate vaccines use with different serotype coverage conditioned a decrease of the vaccine-included and an increase of non-covered. Despite these changes, the global antimicrobial susceptibility patterns to erythromycin and levofloxacin maintained relatively stables. The resistance a penicillin was low, not finding this type of resistant strains in the last study period.
doi_str_mv 10.37201/req/034.2023
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2881246133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2881246133</sourcerecordid><originalsourceid>FETCH-LOGICAL-c218t-7d0c5b005ddc65e8d973cacaaef26db36f79001e21c65a2d78e764bb1b33de9b3</originalsourceid><addsrcrecordid>eNo9kU1v1DAQhi0EotvCkSvykQNp_bWxc0RVoZUWgRCco4k9WVx549R2IvXv8cvwtgunkWaemXekh5B3nF1KLRi_SvhwxaS6FEzIF2TDO2OabsvNS7JhgqtGKtGdkfOc7xlTUnX8NTmT2mipldqQPzdrDEvxcaJxpOU30owplscZM7WwZD_tqZ9WyH5FOk-4HKKN1kKgzmeEjBRCrIxgzDT1BVFpCnSHKwYq6PdlCN7S25hnX-rSKeMruOQd_YH7GvzxuJIwwNMXJR4Jn2rThppfW3Xs_DhiwqlQG6f7ZQ8F6QrW-gnzG_JqhJDx7alekF-fb35e3za7b1_urj_tGiu4KY12zG4HxrbO2XaLxnVaWrAAOIrWDbIddccYR8HrGITTBnWrhoEPUjrsBnlBPjzfnVN8WDCX_uCzxRBgwrjkXhjDhWq5lBVtnlGbYs4Jx35O_gDpseesf9LWV2191dYftVX-_en0MhzQ_af_eZJ_Aa_nloo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2881246133</pqid></control><display><type>article</type><title>Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Zaragoza Vargas, G ; Cacho Calvo, J ; Martínez-Arce, R ; Molina Arana, D ; Ramos Blázquez, B ; Pérez Abeledo, M ; Sanz Moreno, J C</creator><creatorcontrib>Zaragoza Vargas, G ; Cacho Calvo, J ; Martínez-Arce, R ; Molina Arana, D ; Ramos Blázquez, B ; Pérez Abeledo, M ; Sanz Moreno, J C</creatorcontrib><description>The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022. 313 of S. pneumoniae strains were studied. Serotyping was carried out by latex agglutination (Pneumotest-latex) and the Quellung reaction. In addition, the minimal inhibitory concentration (MIC) was determined against penicillin, erythromycin and levofloxacin by the concentration gradient method (E-test) according the EUCAST breakpoints. The most frequent serotypes throughout the study period were 8, 3, 19A, 1, 11A and 22F corresponding to 46.6% of the isolates. Along 2008-2012 the serotypes 3, 1, 19A, 7F, 6C and 11A represented altogether 53.6% of the isolates. Between 2013 and 2017 the serotypes 3, 8, 12F, 19A, 22F and 19F grouped 51% of the isolates. During 2018-2022 the serotypes 8, 3, 11A, 15A, 4 and 6C included the 55.5% of the cases. In total 5 strains (1.6%) were penicillin resistant, 64 (20.4%) erythromycin resistant and 11 (3.5%) levofloxacin resistant. The MIC50 and MIC90 levels maintained stables along the time. The conjugate vaccines use with different serotype coverage conditioned a decrease of the vaccine-included and an increase of non-covered. Despite these changes, the global antimicrobial susceptibility patterns to erythromycin and levofloxacin maintained relatively stables. The resistance a penicillin was low, not finding this type of resistant strains in the last study period.</description><identifier>ISSN: 0214-3429</identifier><identifier>EISSN: 1988-9518</identifier><identifier>DOI: 10.37201/req/034.2023</identifier><identifier>PMID: 37873744</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>Anti-Bacterial Agents - pharmacology ; Erythromycin - pharmacology ; Hospitals, Public ; Humans ; Infant ; Levofloxacin - pharmacology ; Microbial Sensitivity Tests ; Penicillins - pharmacology ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention &amp; control ; Pneumococcal Vaccines ; Serogroup ; Serotyping ; Streptococcus pneumoniae ; Vaccines, Conjugate</subject><ispartof>Revista española de quimioterapia, 2023-12, Vol.36 (6), p.597-603</ispartof><rights>The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-5090-9437 ; 0000-0002-1453-8536</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37873744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaragoza Vargas, G</creatorcontrib><creatorcontrib>Cacho Calvo, J</creatorcontrib><creatorcontrib>Martínez-Arce, R</creatorcontrib><creatorcontrib>Molina Arana, D</creatorcontrib><creatorcontrib>Ramos Blázquez, B</creatorcontrib><creatorcontrib>Pérez Abeledo, M</creatorcontrib><creatorcontrib>Sanz Moreno, J C</creatorcontrib><title>Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines</title><title>Revista española de quimioterapia</title><addtitle>Rev Esp Quimioter</addtitle><description>The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022. 313 of S. pneumoniae strains were studied. Serotyping was carried out by latex agglutination (Pneumotest-latex) and the Quellung reaction. In addition, the minimal inhibitory concentration (MIC) was determined against penicillin, erythromycin and levofloxacin by the concentration gradient method (E-test) according the EUCAST breakpoints. The most frequent serotypes throughout the study period were 8, 3, 19A, 1, 11A and 22F corresponding to 46.6% of the isolates. Along 2008-2012 the serotypes 3, 1, 19A, 7F, 6C and 11A represented altogether 53.6% of the isolates. Between 2013 and 2017 the serotypes 3, 8, 12F, 19A, 22F and 19F grouped 51% of the isolates. During 2018-2022 the serotypes 8, 3, 11A, 15A, 4 and 6C included the 55.5% of the cases. In total 5 strains (1.6%) were penicillin resistant, 64 (20.4%) erythromycin resistant and 11 (3.5%) levofloxacin resistant. The MIC50 and MIC90 levels maintained stables along the time. The conjugate vaccines use with different serotype coverage conditioned a decrease of the vaccine-included and an increase of non-covered. Despite these changes, the global antimicrobial susceptibility patterns to erythromycin and levofloxacin maintained relatively stables. The resistance a penicillin was low, not finding this type of resistant strains in the last study period.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Erythromycin - pharmacology</subject><subject>Hospitals, Public</subject><subject>Humans</subject><subject>Infant</subject><subject>Levofloxacin - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>Penicillins - pharmacology</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention &amp; control</subject><subject>Pneumococcal Vaccines</subject><subject>Serogroup</subject><subject>Serotyping</subject><subject>Streptococcus pneumoniae</subject><subject>Vaccines, Conjugate</subject><issn>0214-3429</issn><issn>1988-9518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kU1v1DAQhi0EotvCkSvykQNp_bWxc0RVoZUWgRCco4k9WVx549R2IvXv8cvwtgunkWaemXekh5B3nF1KLRi_SvhwxaS6FEzIF2TDO2OabsvNS7JhgqtGKtGdkfOc7xlTUnX8NTmT2mipldqQPzdrDEvxcaJxpOU30owplscZM7WwZD_tqZ9WyH5FOk-4HKKN1kKgzmeEjBRCrIxgzDT1BVFpCnSHKwYq6PdlCN7S25hnX-rSKeMruOQd_YH7GvzxuJIwwNMXJR4Jn2rThppfW3Xs_DhiwqlQG6f7ZQ8F6QrW-gnzG_JqhJDx7alekF-fb35e3za7b1_urj_tGiu4KY12zG4HxrbO2XaLxnVaWrAAOIrWDbIddccYR8HrGITTBnWrhoEPUjrsBnlBPjzfnVN8WDCX_uCzxRBgwrjkXhjDhWq5lBVtnlGbYs4Jx35O_gDpseesf9LWV2191dYftVX-_en0MhzQ_af_eZJ_Aa_nloo</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Zaragoza Vargas, G</creator><creator>Cacho Calvo, J</creator><creator>Martínez-Arce, R</creator><creator>Molina Arana, D</creator><creator>Ramos Blázquez, B</creator><creator>Pérez Abeledo, M</creator><creator>Sanz Moreno, J C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5090-9437</orcidid><orcidid>https://orcid.org/0000-0002-1453-8536</orcidid></search><sort><creationdate>20231201</creationdate><title>Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines</title><author>Zaragoza Vargas, G ; Cacho Calvo, J ; Martínez-Arce, R ; Molina Arana, D ; Ramos Blázquez, B ; Pérez Abeledo, M ; Sanz Moreno, J C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c218t-7d0c5b005ddc65e8d973cacaaef26db36f79001e21c65a2d78e764bb1b33de9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Erythromycin - pharmacology</topic><topic>Hospitals, Public</topic><topic>Humans</topic><topic>Infant</topic><topic>Levofloxacin - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>Penicillins - pharmacology</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention &amp; control</topic><topic>Pneumococcal Vaccines</topic><topic>Serogroup</topic><topic>Serotyping</topic><topic>Streptococcus pneumoniae</topic><topic>Vaccines, Conjugate</topic><toplevel>online_resources</toplevel><creatorcontrib>Zaragoza Vargas, G</creatorcontrib><creatorcontrib>Cacho Calvo, J</creatorcontrib><creatorcontrib>Martínez-Arce, R</creatorcontrib><creatorcontrib>Molina Arana, D</creatorcontrib><creatorcontrib>Ramos Blázquez, B</creatorcontrib><creatorcontrib>Pérez Abeledo, M</creatorcontrib><creatorcontrib>Sanz Moreno, J C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Revista española de quimioterapia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaragoza Vargas, G</au><au>Cacho Calvo, J</au><au>Martínez-Arce, R</au><au>Molina Arana, D</au><au>Ramos Blázquez, B</au><au>Pérez Abeledo, M</au><au>Sanz Moreno, J C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines</atitle><jtitle>Revista española de quimioterapia</jtitle><addtitle>Rev Esp Quimioter</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>36</volume><issue>6</issue><spage>597</spage><epage>603</epage><pages>597-603</pages><issn>0214-3429</issn><eissn>1988-9518</eissn><abstract>The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022. 313 of S. pneumoniae strains were studied. Serotyping was carried out by latex agglutination (Pneumotest-latex) and the Quellung reaction. In addition, the minimal inhibitory concentration (MIC) was determined against penicillin, erythromycin and levofloxacin by the concentration gradient method (E-test) according the EUCAST breakpoints. The most frequent serotypes throughout the study period were 8, 3, 19A, 1, 11A and 22F corresponding to 46.6% of the isolates. Along 2008-2012 the serotypes 3, 1, 19A, 7F, 6C and 11A represented altogether 53.6% of the isolates. Between 2013 and 2017 the serotypes 3, 8, 12F, 19A, 22F and 19F grouped 51% of the isolates. During 2018-2022 the serotypes 8, 3, 11A, 15A, 4 and 6C included the 55.5% of the cases. In total 5 strains (1.6%) were penicillin resistant, 64 (20.4%) erythromycin resistant and 11 (3.5%) levofloxacin resistant. The MIC50 and MIC90 levels maintained stables along the time. The conjugate vaccines use with different serotype coverage conditioned a decrease of the vaccine-included and an increase of non-covered. Despite these changes, the global antimicrobial susceptibility patterns to erythromycin and levofloxacin maintained relatively stables. The resistance a penicillin was low, not finding this type of resistant strains in the last study period.</abstract><cop>Spain</cop><pmid>37873744</pmid><doi>10.37201/req/034.2023</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-5090-9437</orcidid><orcidid>https://orcid.org/0000-0002-1453-8536</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0214-3429
ispartof Revista española de quimioterapia, 2023-12, Vol.36 (6), p.597-603
issn 0214-3429
1988-9518
language eng ; spa
recordid cdi_proquest_miscellaneous_2881246133
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Anti-Bacterial Agents - pharmacology
Erythromycin - pharmacology
Hospitals, Public
Humans
Infant
Levofloxacin - pharmacology
Microbial Sensitivity Tests
Penicillins - pharmacology
Pneumococcal Infections - epidemiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines
Serogroup
Serotyping
Streptococcus pneumoniae
Vaccines, Conjugate
title Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T17%3A11%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evolution%20of%20the%20serotypes%20causing%20invasive%20pneumococcal%20disease%20along%202008-2022%20in%20a%20Level%202%20Public%20Hospital%20of%20the%20Madrid%20Region,%20in%20relation%20to%20their%20inclusion%20in%20different%20conjugate%20vaccines&rft.jtitle=Revista%20espa%C3%B1ola%20de%20quimioterapia&rft.au=Zaragoza%20Vargas,%20G&rft.date=2023-12-01&rft.volume=36&rft.issue=6&rft.spage=597&rft.epage=603&rft.pages=597-603&rft.issn=0214-3429&rft.eissn=1988-9518&rft_id=info:doi/10.37201/req/034.2023&rft_dat=%3Cproquest_cross%3E2881246133%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2881246133&rft_id=info:pmid/37873744&rfr_iscdi=true